Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 98 articles:
HTML format



Single Articles


    June 2022
  1. RUCK T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, et al
    Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
    Brain. 2022;145:1711-1725.
    PubMed     Abstract available


  2. BRADL M
    From astrocyte destruction to axon injury: watching lesion evolution in experimental neuromyelitis optica.
    Brain. 2022;145:1581-1583.
    PubMed    


  3. HERWERTH M, Kenet S, Schifferer M, Winkler A, et al
    A new form of axonal pathology in a spinal model of neuromyelitis optica.
    Brain. 2022;145:1726-1742.
    PubMed     Abstract available


  4. ADRICHEM ME, Lucke IM, Vrancken AFJE, Goedee HS, et al
    Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2022;145:1641-1652.
    PubMed     Abstract available


  5. COLES A
    Campath, clones and the cause of autoimmunity.
    Brain. 2022;145:1579-1580.
    PubMed    


  6. MADSEN MAJ, Wiggermann V, Marques MFM, Lundell H, et al
    Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study.
    Brain. 2022 Jun 2. pii: 6599027. doi: 10.1093.
    PubMed     Abstract available


    May 2022
  7. GUO Y, Lennon VA, Parisi JE, Popescu B, et al
    Spectrum of sublytic astrocytopathy in neuromyelitis optica.
    Brain. 2022;145:1379-1390.
    PubMed     Abstract available


  8. BERNARD-VALNET R, Frieser D, Nguyen XH, Khajavi L, et al
    Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy.
    Brain. 2022 May 13. pii: 6581499. doi: 10.1093.
    PubMed     Abstract available


  9. LEE WJ, Lee HS, Kim DY, Lee HS, et al
    Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes.
    Brain. 2022 May 5. pii: 6580901. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  10. CORNBLATH DR, van Doorn PA, Hartung HP, Merkies ISJ, et al
    Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
    Brain. 2022;145:887-896.
    PubMed     Abstract available


    March 2022
  11. STRIPPEL C, Herrera-Rivero M, Wendorff M, Tietz AK, et al
    A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies.
    Brain. 2022 Mar 28. pii: 6555060. doi: 10.1093.
    PubMed     Abstract available


  12. PORTACCIO E, Bellinvia A, Fonderico M, Pasto L, et al
    Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
    Brain. 2022 Mar 24. pii: 6553893. doi: 10.1093.
    PubMed     Abstract available


  13. SHAMS H, Shao X, Santaniello A, Kirkish G, et al
    Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.
    Brain. 2022 Mar 7. pii: 6542574. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  14. PERNIN F, Luo J, Cui QL, Blain M, et al
    Diverse injury responses of human oligodendrocyte to mediators implicated in multiple sclerosis.
    Brain. 2022 Feb 24. pii: 6535861. doi: 10.1093.
    PubMed     Abstract available


  15. KEH RYS, Scanlon S, Datta-Nemdharry P, Donegan K, et al
    COVID-19 vaccination and Guillain-Barre syndrome: analyses using the National Immunoglobulin Database.
    Brain. 2022 Feb 18. pii: 6532037. doi: 10.1093.
    PubMed     Abstract available


  16. LUBLIN FD, Haring DA, Ganjgahi H, Ocampo A, et al
    How patients with multiple sclerosis acquire disability.
    Brain. 2022 Feb 1. pii: 6519354. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  17. NISHIHARA H, Perriot S, Gastfriend BD, Steinfort M, et al
    Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis.
    Brain. 2022 Jan 27. pii: 6516047. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  18. GREEN AJ
    Socioeconomic disadvantage in multiple sclerosis: does inequality act on the substrate for disability?
    Brain. 2021 Dec 20. pii: 6470562. doi: 10.1093.
    PubMed    


  19. CAROTENUTO A, Cacciaguerra L, Pagani E, Preziosa P, et al
    Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.
    Brain. 2021 Dec 17. pii: 6469024. doi: 10.1093.
    PubMed     Abstract available


  20. NTRANOS A, Park HJ, Wentling M, Tolstikov V, et al
    Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.
    Brain. 2021 Dec 11. pii: 6459638. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  21. LIEBMANN M, Korn L, Janoschka C, Albrecht S, et al
    Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity.
    Brain. 2021;144:3126-3141.
    PubMed     Abstract available


  22. ZIEGLER D, Bonhof GJ, Strom A, Strassburger K, et al
    Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years.
    Brain. 2021;144:3251-3263.
    PubMed     Abstract available


    October 2021
  23. VASILEIOU ES, Filippatou AG, Pimentel Maldonado D, Kalaitzidis G, et al
    Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis.
    Brain. 2021 Oct 29. pii: 6414110. doi: 10.1093.
    PubMed     Abstract available


  24. RODGERS J, Friede T, Vonberg FW, Constantinescu CS, et al
    The impact of smoking cessation on multiple sclerosis disease progression.
    Brain. 2021 Oct 8. pii: 6384574. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  25. LUIJTEN LWG, Leonhard SE, van der Eijk AA, Doets AY, et al
    Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study.
    Brain. 2021 Sep 23. pii: 6373760. doi: 10.1093.
    PubMed     Abstract available


  26. TAKAI Y, Misu T, Suzuki H, Takahashi T, et al
    Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
    Brain. 2021;144:2401-2415.
    PubMed     Abstract available


    August 2021
  27. NAUGHTON M, de la Fuente AG
    Autoantibodies and microglia: boon or bane?
    Brain. 2021 Aug 11. pii: 6348165. doi: 10.1093.
    PubMed    


    July 2021
  28. BENALLEGUE N, Kebir H, Kapoor R, Crockett A, et al
    The hedgehog pathway suppresses neuropathogenesis in CD4 T cell-driven inflammation.
    Brain. 2021;144:1670-1683.
    PubMed     Abstract available


  29. JENSEN TS, Karlsson P, Gylfadottir SS, Andersen ST, et al
    Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management.
    Brain. 2021;144:1632-1645.
    PubMed     Abstract available


  30. MITSDOERFFER M, Di Liberto G, Dotsch S, Sie C, et al
    Corrigendum to: Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity.
    Brain. 2021 Jul 14. pii: 6321151. doi: 10.1093.
    PubMed    


    June 2021
  31. BITTNER S, Oh J, Havrdova EK, Tintore M, et al
    The potential of serum neurofilament as biomarker for multiple sclerosis.
    Brain. 2021 Jun 28. pii: 6310737. doi: 10.1093.
    PubMed     Abstract available


  32. COLLORONE S, Prados F, Kanber B, Cawley NM, et al
    Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event.
    Brain. 2021;144:1409-1421.
    PubMed     Abstract available


  33. HAIDER L, Prados F, Chung K, Goodkin O, et al
    Cortical involvement determines impairment 30 years after a clinically isolated syndrome.
    Brain. 2021;144:1384-1395.
    PubMed     Abstract available


  34. PELLERIN K, Rubino SJ, Burns JC, Smith BA, et al
    MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.
    Brain. 2021 Jun 18. pii: 6305830. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  35. GRANZIERA C, Wuerfel J, Barkhof F, Calabrese M, et al
    Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.
    Brain. 2021 May 10. pii: 6273092. doi: 10.1093.
    PubMed     Abstract available


  36. VAN DOORN PA, Hadden RDM, Van den Bergh PYK
    Elucidating autoimmune nodopathies and the CIDP spectrum.
    Brain. 2021;144:1043-1045.
    PubMed    


  37. PASCUAL-GONI E, Fehmi J, Lleixa C, Martin-Aguilar L, et al
    Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2021;144:1183-1196.
    PubMed     Abstract available


    April 2021
  38. FLECK AK, Hucke S, Teipel F, Eschborn M, et al
    Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity.
    Brain. 2021 Apr 26. pii: 6252379. doi: 10.1093.
    PubMed     Abstract available


  39. GHORBANI S, Yong VW
    The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis.
    Brain. 2021 Apr 23. pii: 6247173. doi: 10.1093.
    PubMed     Abstract available


  40. PARDINI M, Brown JWL, Magliozzi R, Reynolds R, et al
    Surface-in pathology in multiple sclerosis: a new view on pathogenesis?
    Brain. 2021 Apr 20. pii: 6238675. doi: 10.1093.
    PubMed     Abstract available


  41. PISA M, Croese T, Dalla Costa G, Guerrieri S, et al
    Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes.
    Brain. 2021 Apr 8. pii: 6215108. doi: 10.1093.
    PubMed     Abstract available


  42. LUCCHESE G, Floel A
    Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry.
    Brain. 2021 Apr 3. pii: 6209729. doi: 10.1093.
    PubMed    


  43. LUNN MP, Carr AC, Keddie S, Pakpoor J, et al
    Reply: Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry and Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome and Unclear association between COVID-19 and Guillain-Barre syndrome and Currently avai
    Brain. 2021 Apr 3. pii: 6209732. doi: 10.1093.
    PubMed    


  44. FOSCHI M, D'Anna L, Abdelhak A, Mayer B, et al
    Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209733. doi: 10.1093.
    PubMed    


  45. GONZALEZ DEL CASTILLO J, Porta-Etessam J, Miro O
    Currently available data regarding the potential association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209731. doi: 10.1093.
    PubMed    


    March 2021
  46. ONTANEDA D, Raza PC, Mahajan KR, Arnold DL, et al
    Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement.
    Brain. 2021 Mar 23. pii: 6184142. doi: 10.1093.
    PubMed     Abstract available


  47. VOGRIG A, Moritz CP, Camdessanche JP, Tholance Y, et al
    Unclear association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Mar 23. pii: 6181752. doi: 10.1093.
    PubMed    


  48. BHARGAVA P, Kim S, Reyes AA, Grenningloh R, et al
    Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition.
    Brain. 2021 Mar 16. pii: 6173632. doi: 10.1093.
    PubMed     Abstract available


  49. SABEL CE, Pearson JF, Mason DF, Willoughby E, et al
    The latitude gradient for multiple sclerosis prevalence is established in the early lifecourse.
    Brain. 2021 Mar 11. pii: 6168130. doi: 10.1093.
    PubMed     Abstract available


  50. RAHMANZADEH R, Lu PJ, Barakovic M, Weigel M, et al
    Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging.
    Brain. 2021 Mar 9. pii: 6164965. doi: 10.1093.
    PubMed     Abstract available


  51. MITSDORFFER M, Di Liberto G, Dotsch S, Sie C, et al
    Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity.
    Brain. 2021 Mar 9. pii: 6164962. doi: 10.1093.
    PubMed     Abstract available


  52. XU Y, Smith KA, Hiyoshi A, Piehl F, et al
    Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis.
    Brain. 2021 Mar 9. pii: 6164964. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  53. KILPATRICK TJ, Binder MD
    Neuregulin therapy for multiple sclerosis: an each-way bet?
    Brain. 2021;144:6-8.
    PubMed    


    January 2021
  54. DAL-BIANCO A, Grabner G, Kronnerwetter C, Weber M, et al
    Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.
    Brain. 2021 Jan 23. pii: 6114694. doi: 10.1093.
    PubMed     Abstract available



  55. Corrigendum to: Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis.
    Brain. 2021 Jan 11. pii: 6082765. doi: 10.1093.
    PubMed    


    December 2020
  56. KIM K, Probstel AK, Baumann R, Dyckow J, et al
    Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis.
    Brain. 2020 Dec 29. pii: 6055080. doi: 10.1093.
    PubMed     Abstract available


  57. HALDER SK, Milner R
    Hypoxia in multiple sclerosis; is it the chicken or the egg?
    Brain. 2020 Dec 22. pii: 6044083. doi: 10.1093.
    PubMed     Abstract available


  58. LUNN MP, Cornblath DR, Jacobs BC, Querol L, et al
    COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations.
    Brain. 2020 Dec 14. pii: 6031904. doi: 10.1093.
    PubMed    


  59. KEDDIE S, Pakpoor J, Mousele C, Pipis M, et al
    Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2020 Dec 14. pii: 6031905. doi: 10.1093.
    PubMed     Abstract available


  60. KATARIA H, Hart CG, Alizadeh A, Cossoy M, et al
    Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032483. doi: 10.1093.
    PubMed     Abstract available


  61. HOHLFELD R, Beltran E, Gerdes LA, Dornmair K, et al
    Tissue-resident CD8+ memory T cells in multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032479. doi: 10.1093.
    PubMed    


  62. SMOLDERS J, Fransen NL, Huitinga I, Hamann J, et al
    Reply: Tissue-resident CD8+ memory T cells in multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032480. doi: 10.1093.
    PubMed    


  63. EFTIMOV F, Lucke IM, Querol LA, Rajabally YA, et al
    Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2020;143:3214-3224.
    PubMed     Abstract available


  64. PATERSON RW, Brown RL, Vivekanandam V, Foulkes AJM, et al
    Reply: Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?
    Brain. 2020;143:e101.
    PubMed    


  65. KARAPANAYIOTIDES T, Geka E, Prassopoulos P, Koutroulou I, et al
    Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?
    Brain. 2020;143:e100.
    PubMed    


  66. CAO A, Rohaut B, Le Guennec L, Saheb S, et al
    Severe COVID-19-related encephalitis can respond to immunotherapy.
    Brain. 2020;143:e102.
    PubMed    


    November 2020
  67. PETROU P, Kassis I, Levin N, Paul F, et al
    Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Brain. 2020 Nov 30. pii: 6012789. doi: 10.1093.
    PubMed     Abstract available


  68. PETZOLD A, Chua SYL, Khawaja AP, Keane PA, et al
    Retinal asymmetry in multiple sclerosis.
    Brain. 2020 Nov 30. pii: 6012795. doi: 10.1093.
    PubMed     Abstract available


  69. SCHIAVI S, Petracca M, Sun P, Fleysher L, et al
    Non-invasive quantification of inflammation, axonal and myelin injury in multiple sclerosis.
    Brain. 2020 Nov 30. pii: 5999115. doi: 10.1093.
    PubMed     Abstract available


  70. STERIADE C, Titulaer MJ, Vezzani A, Sander JW, et al
    The association between systemic autoimmune disorders and epilepsy and its clinical implications.
    Brain. 2020 Nov 22. pii: 5998333. doi: 10.1093.
    PubMed     Abstract available


  71. DE MEO E, Storelli L, Moiola L, Ghezzi A, et al
    In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology.
    Brain. 2020 Nov 21. pii: 5998271. doi: 10.1093.
    PubMed     Abstract available


  72. MARIANO R, Messina S, Roca-Fernandez A, Leite MI, et al
    Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis.
    Brain. 2020 Nov 18. pii: 5989776. doi: 10.1093.
    PubMed     Abstract available


  73. ELLENBERGER D, Flachenecker P, Fneish F, Frahm N, et al
    Aggressive multiple sclerosis - a matter of measurement and timing.
    Brain. 2020 Nov 11. pii: 5974108. doi: 10.1093.
    PubMed    


  74. KALINCIK T, Malpas CB
    Reply: Aggressive multiple sclerosis - a matter of measurement and timing.
    Brain. 2020 Nov 11. pii: 5974107. doi: 10.1093.
    PubMed    


    October 2020
  75. SUCKSDORFF M, Matilainen M, Tuisku J, Polvinen E, et al
    Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Brain. 2020 Oct 2. pii: 5917253. doi: 10.1093.
    PubMed     Abstract available


  76. GAUDIOSO C, Naismith RT
    Optimizing treatment strategies in paediatric, adult and late-onset multiple sclerosis.
    Brain. 2020;143:2866-2868.
    PubMed    


    September 2020
  77. AMATO MP, Fonderico M, Portaccio E, Pasto L, et al
    Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Brain. 2020 Sep 16. pii: 5906150. doi: 10.1093.
    PubMed     Abstract available


  78. OUELLETTE R, Treaba CA, Granberg T, Herranz E, et al
    7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis.
    Brain. 2020 Sep 16. pii: 5906152. doi: 10.1093.
    PubMed     Abstract available


  79. WAGNON I, Helie P, Bardou I, Regnauld C, et al
    Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor.
    Brain. 2020 Sep 7. pii: 5902131. doi: 10.1093.
    PubMed     Abstract available


  80. GERALDES R, Esiri MM, Perera R, Yee SA, et al
    Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships.
    Brain. 2020 Sep 2. pii: 5900415. doi: 10.1093.
    PubMed     Abstract available


  81. ROOS I, Leray E, Frascoli F, Casey R, et al
    Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
    Brain. 2020;143:2742-2756.
    PubMed     Abstract available


  82. KULLMANN DM
    Editorial.
    Brain. 2020;143:2625.
    PubMed    


  83. RICHARD C, Ruiz A, Cavagna S, Bigotte M, et al
    Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination.
    Brain. 2020;143:2721-2732.
    PubMed     Abstract available


  84. MANNARA F, Radosevic M, Planaguma J, Soto D, et al
    Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis.
    Brain. 2020;143:2709-2720.
    PubMed     Abstract available


    August 2020
  85. BOUMAN PM, Steenwijk MD, Pouwels PJW, Schoonheim MM, et al
    Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis.
    Brain. 2020 Aug 21. pii: 5895168. doi: 10.1093.
    PubMed     Abstract available


  86. CHITNIS T, Aaen G, Belman A, Benson L, et al
    Improved relapse recovery in paediatric compared to adult multiple sclerosis.
    Brain. 2020 Aug 18. pii: 5894047. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  87. SORENSEN PS, Sellebjerg F, Hartung HP, Montalban X, et al
    The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Brain. 2020 Jul 24. pii: 5876125. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  88. JACKLE K, Zeis T, Schaeren-Wiemers N, Junker A, et al
    Molecular signature of slowly expanding lesions in progressive multiple sclerosis.
    Brain. 2020 Jun 24. pii: 5861738. doi: 10.1093.
    PubMed     Abstract available


  89. KERBRAT A, Gros C, Badji A, Bannier E, et al
    Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.
    Brain. 2020 Jun 23. pii: 5861019. doi: 10.1093.
    PubMed     Abstract available


  90. ZEKERIDOU A, Pittock SJ
    Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction.
    Brain. 2020;143:1622-1625.
    PubMed    


    May 2020
  91. RAMBERGER M, Berretta A, Tan JMM, Sun B, et al
    Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.
    Brain. 2020 May 21. pii: 5841730. doi: 10.1093.
    PubMed     Abstract available


  92. FRANSEN NL, Hsiao CC, van der Poel M, Engelenburg HJ, et al
    Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions.
    Brain. 2020 May 13. pii: 5836675. doi: 10.1093.
    PubMed     Abstract available


  93. MALPAS CB, Manouchehrinia A, Sharmin S, Roos I, et al
    Early clinical markers of aggressive multiple sclerosis.
    Brain. 2020 May 9. pii: 5835340. doi: 10.1093.
    PubMed     Abstract available


  94. KADOWAKI A, Quintana FJ
    The NLRP3 inflammasome in progressive multiple sclerosis.
    Brain. 2020;143:1286-1288.
    PubMed    


  95. TAKAI Y, Misu T, Kaneko K, Chihara N, et al
    Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Brain. 2020;143:1431-1446.
    PubMed     Abstract available


    April 2020
  96. DIETRICH M, Koska V, Hecker C, Gottle P, et al
    Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.
    Brain. 2020 Apr 15. pii: 5820386. doi: 10.1093.
    PubMed     Abstract available


  97. MALHOTRA S, Costa C, Eixarch H, Keller CW, et al
    NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.
    Brain. 2020 Apr 13. pii: 5819591. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  98. ROWE J
    Editorial.
    Brain. 2020;143:1.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: